M2 Presswire - FDA grants priority review to Diovan for heart failure indication.
M2 PRESSWIRE-14 June 2001-NOVARTIS: FDA grants priority review to Diovan for heart failure indication (C)1994-2001 M2 COMMUNICATIONS LTD RDATE:13062001 Basel — Novartis today announced that the US Food and Drug Administration (FDA) has granted priority review status to the supplemental new drug application (sNDA) for Diovan (valsartan) for the treatment of heart failure.
Related Results
DiovanDiovanDiovan dosesFDA approves DiovanNew indication for diovan
Diovan is currently indicated for treating high blood pressure and is the first angiotensin II receptor blocker (ARB) to seek an indication beyond hypertension in the US. Priority review status is …
Read the rest of this article with a Free Trial at HighBeam Research.
